Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes

Psychological Medicine

Volumn 35, Issue 3, 2005, Pages 433-441

  Wichers, M C ^a   Koek, G H ^b   Robaeys, G ^c   Praamstra, A J ^a   Maes, M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BENZODIAZEPINE DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANXIETY; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG INDUCED DISEASE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEART PALPITATION; HEPATITIS C; HUMAN; IRRITABILITY; MALE; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PANIC; PERSISTENT VEGETATIVE STATE; PREDICTION; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; SYNCOPE; THORAX PAIN;

ADULT; AFFECT; COGNITION DISORDERS; DEPRESSIVE DISORDER; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNE SYSTEM; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 14944345913     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291704003526     Document Type: Article

References (38)

1. Besedovsky, H. O. & del Rey, A. (1996). Immune-neuro-endocrine interactions: facts and hypotheses. Endocrine Reviews 17, 64-102.
2. Blatteis, C. M. (2000). The afferent signalling of fever. Journal of Physiology 526, 470.
3. Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F. & Maes, M. (2002a). Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. Journal of Affective Disorders 72, 237-241.
4. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H. & Maes, M. (2002b). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Journal of Clinical Psychopharmacology 22, 86-90.
5. Capuron, L., Gumnick, J. F., Musselman, D. L., Lawson, D. H., Reemsnyder, A., Nemeroff, C. B. & Miller, A. H. (2002). Neurobehavioral effects of interferon-alpha in cancer patients. phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643-652.
6. Charlton, B. G. (2000). The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Medical Hypotheses 54, 126-130.
7. Checkley, S. (1996). The neuroendocrinology of depression and chronic stress. British Medical Bulletin 52, 597-617.
8. Dalakas, M. C., Mock, V. & Hawkins, M. J. (1998). Fatigue: definitions, mechanisms, and paradigms for study. Seminars in Oncology 25 (Suppl. 1), 48-53.
9. Dieperink, E., Ho, S. B., Thuras, P. & Willenbring, M. L. (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44, 104-112.
10. Dunn, A. J. & Swiergiel, A. H. (1998). The role of cytokines in infection-related behavior. Annals of the New York Academy of Science 840, 577-585.
11. Dusheiko, G. (1997). Side effects of alpha interferon in chronic hepatitis C. Hepatology 26 (3 Suppl. 1), 112S-121S.
12. Elsehety, A. & Bertorini, T. E. (1997). Neurologic and neuropsychiatric complications of Crohn's disease. Southern Medical Journal 90, 606-610.
13. Foley, F. W., Traugott, U., LaRocca, N. G., Smith, C. R., Perlman, K. R., Caruso, L. S. & Scheinberg, L. C. (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology 49, 238-244.
14. Graeff, F. G., Guimaraes, F. S., De Andrade, T. G. & Deakin, J. F. (1996). Role of 5-HT in stress, anxiety, and depression. Pharmacology Biochemistry and Behavior 54, 129-141.
15. Hall, S. & Smith, A. (1996). Investigation of the effects and after-effects of naturally occurring upper respiratory tract illnesses on mood and performance. Physiology and Behavior 59 569-577.
16. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
17. Hart, B. L. (1988). Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Reviews 12, 123-137.
18. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., Meyers, C. A. & Howell, C. D. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 7 942-947.
19. Horikawa, N., Yamazaki, T., Izumi, N. & Uchihara, M. (2003). Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. General Hospital Psychiatry 25, 34-38.
20. John, C. D. & Buckingham, J. C. (2003). Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Current Opinion in Pharmacology 3, 78-84.
21. Keating, G. M. & Curran, M. P. (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63, 701-730.
22. Kelley, K. W., Bluthe, R. M., Dantzer, R., Zhou, J. H., Shen, W. H., Johnson, R. W. & Broussard, S. R. (2003). Cytokine-induced sickness behavior. Brain Behavior and Immunity 17 (1 Suppl.), 112-118.
23. Licinio, J., Kling, M. A. & Hauser, P. (1998). Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Seminars in Oncology 25 (1 Suppl. 1), 30-38.
24. Maes, M. (1995). Evidence for an immune response in major depression: a review and hypothesis. Progress in Neuropsychopharmacology and Biological Psychiatry 19, 11-38.
25. Meijer, A., Zakay-Rones, Z. & Morag, A. (1988). Post-influenzal psychiatric disorder in adolescents. Acta Psychiatrica Scandinavica 78, 176-181.
26. Minden, S. L. & Schiffer, R. B. (1990). Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Archives of Neurology 47, 98-104.
27. Montgomery, S. A. & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
28. Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B. & Miller, A. H. (2001). Paroxetine for the prevention of depression induced by high-dose interferon alfa. New England Journal of Medicine 344, 961-966.
29. Parker, J., Smarr, K., Anderson, S., Hewett, J., Walker, S., Bridges, A. & Caldwell, W. (1992). Relationship of changes in helplessness and depression to disease activity in rheumatoid arthritis. Journal of Rheumatology 19, 1901-1905.
30. Pincus, T., Griffith, J., Pearce, S. & Isenberg, D. (1996). Prevalence of self-reported depression in patients with rheumatoid arthritis. British Journal of Rheumatology 35, 879-883.
31. Schaefer, M., Engelbrecht, M. A., Gut, O., Fiebich, B. L., Bauer, J., Schmidt, F., Grunze, H. & Lieb, K. (2002). Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Progress in Neuropsychopharmacology and Biological Psychiatry 26, 731-746.
32. Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A. & Loeschke, K. (2003). Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 37, 443-451.
33. Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R. & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33; quiz, 34 57.
34. Smets, E. M., Garssen, B., Bonke, B. & De Haes, J. C. (1995). The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research 39, 315-325.
35. StataCorp (2001). STATA statistical software: release 7.0. Stata Corporation: College Station, TX
36. Stone, T. W. (2001). Endogenous neurotoxins from tryptopban. Toxicon 39, 61-73.
37. Van Gool, A. R., Kruit, W. H., Engels, F. K., Stoter, G., Bannink, M. & Eggermont, A. M. (2003). Neuropsychiatric side effects of interferon-alfa therapy. Pharmacy World and Science 25, 11-20.
38. Wirleitner, B., Neurauter, G., Schrocksnadel, K., Frick, B. & Fuchs, D. (2003). Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Current Medicinal Chemistry 10, 1581-1591.